01:15:50 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-02-15 Bokslutskommuniké 2023
2023-11-14 Kvartalsrapport 2023-Q3
2023-08-23 Kvartalsrapport 2023-Q2
2023-05-25 Kvartalsrapport 2023-Q1
2023-04-20 Årsstämma 2023
2023-02-16 Bokslutskommuniké 2022
2022-11-15 Kvartalsrapport 2022-Q3
2022-08-23 Kvartalsrapport 2022-Q2
2022-05-24 Kvartalsrapport 2022-Q1
2022-04-29 Ordinarie utdelning BGBIO 0.00 NOK
2022-04-28 Årsstämma 2022
2022-02-16 Bokslutskommuniké 2021
2022-01-06 Extra Bolagsstämma 2022
2021-11-16 Kvartalsrapport 2021-Q3
2021-08-17 Kvartalsrapport 2021-Q2
2021-05-19 Kvartalsrapport 2021-Q1
2021-03-22 Ordinarie utdelning BGBIO 0.00 NOK
2021-03-19 Årsstämma 2021
2021-02-10 Bokslutskommuniké 2020
2020-12-09 Extra Bolagsstämma 2020
2020-11-17 Kvartalsrapport 2020-Q3
2020-08-18 Kvartalsrapport 2020-Q2
2020-05-19 Kvartalsrapport 2020-Q1
2020-03-17 Ordinarie utdelning BGBIO 0.00 NOK
2020-03-16 Årsstämma 2020
2020-02-11 Bokslutskommuniké 2019
2019-11-19 Kvartalsrapport 2019-Q3
2019-08-19 Kvartalsrapport 2019-Q2
2019-05-08 Kvartalsrapport 2019-Q1
2019-03-14 Ordinarie utdelning BGBIO 0.00 NOK
2019-03-13 Årsstämma 2019
2019-02-19 Bokslutskommuniké 2018
2018-11-13 Kvartalsrapport 2018-Q3
2018-08-21 Kvartalsrapport 2018-Q2
2018-05-15 Kvartalsrapport 2018-Q1
2018-05-15 Ordinarie utdelning BGBIO 0.00 NOK
2018-05-14 Årsstämma 2018
2018-03-09 Extra Bolagsstämma 2018
2018-02-13 Bokslutskommuniké 2017
2017-11-17 Kvartalsrapport 2017-Q3
2017-08-18 Kvartalsrapport 2017-Q2
2017-05-23 Kvartalsrapport 2017-Q1
2017-03-23 Ordinarie utdelning BGBIO 0.00 NOK
2017-03-22 Årsstämma 2017
2016-06-22 Ordinarie utdelning BGBIO 0.00 NOK
2016-06-21 Årsstämma 2016
2015-06-23 Ordinarie utdelning BGBIO 0.00 NOK
2015-06-22 Årsstämma 2015

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriBioteknik
BerGenBio är ett norskt onkologibolag. Idag bedriver bolaget forskning och utveckling av hämmande läkemedel för behandling av aggressiva cancertyper. Bolaget har utvecklat ett flertal produkter vars sammansättning ämnar blockera proteinet AXL, ett protein positivt relaterat med spridning av cancercellerna. Bolaget grundades under 2007 och har sitt huvudkontor i Bergen.
2021-07-12 14:12:15
· Survival 96.6% vs 91.2%
· Significantly reduced likelihood (69%) of progression to ventilation in
higher severity cohort
· Significantly increased likelihood (88%) of shorter time to recovery or
discharge in higher severity cohort
· Clinical evidence of anti-viral mechanism of action
· Preclinical analysis highlights bemcentinib's potential against COVID-19
variants

Bergen, Norway, 12 July 2021?- BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need, has presented a combined analysis of data from two
Phase II studies investigating bemcentinib in hospitalised COVID-19 patients at
the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID).

Data was presented from the UKRI PhaseII ACCORD2 platform study, sponsored by
University Hospital Southampton, UK and BGBC020, BerGenBio's open-label Phase II
study conducted in South Africa and India. In total, 179 eligible patients were
enrolled across both studies between May 2020 and March 2021, randomly allocated
on an open-label basis to treatment with bemcentinib in addition to standard of
care (SoC) compared to SoC alone. The two studies shared an identical design,
and combined data presented today showed encouraging survival benefit of 96.5%
vs 91.2%, with fewer deaths within 29 days of enrolment in bemcentinib treated
patients (1 of 30 and 2 of 58, 3.4%) versus SoC (5 of 34 and 3 of 57, 8.8%),
respectively.

As previously reported for BGBC020, a post-hoc analysis identified a sub-group
of patients with higher disease severity on enrolment within 24 hours of
admission to hospital in whom evidence of a treatment benefit with bemcentinib
was observed. Patients in the subgroup were receiving oxygen (Grade 4) or non
-invasive ventilation (Grade 5) and recorded serum levels of the inflammatory
marker C-Reactive Protein (CRP) greater than 30mg/L. This subgroup represents
more than 60% of the patients in the combined study population, and the
previously reported treatment benefit in this group of patients in India and
South Africa is reproduced in analysis of the patients studied in the UK.

Across both studies, evaluation of the primary endpoint of time to recovery or
discharge, in this defined patient subgroup with higher baseline disease
severity, showed there was a statistically significant greater likelihood of
faster time to recovery or hospital discharge with bemcentinib added to SoC,
compared to SoC alone